International Journal of Drug Delivery Technology
Volume 14, Issue 3

Design, Development and Characterization of a Niosomal Anticancer Drug Delivery System Formulation

Rajesh S. Palva1, Yadav Vikas K1, Rajnikant M. Suthar1, Rahul Shete2

1Department of Pharmaceutics, A.R. College of Pharmacy & G.H Patel Institute of Pharmacy, Anand, Gujarat, India.

2Scientific Manager Quality by Design - R&D) of Biocon Pharma Limited – SEZ Unit. 

Received: 24th February, 2024; Revised: 28th March, 2024; Accepted: 10th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

Objective: This study set out to create a niosomal formulation of ceritinib with the goal of delivering the medication specifically to the lungs while reducing side effects.

Method: Span 60, cholesterol and DCP were combined with the thin film hydration process to create niosomes. A central composite design was used to optimize the formulation, and the design of experiments was used to assess the impact of various variables on vesicle size and entrapment efficiency. The TEM and in-vitro drug release tests were used to analyse the optimized niosomes.

Results: 395.5 nm was the particle size, 75.28% entrapment efficiency, 0.321 polydispersity Index (PDI), and -28.0 mV zeta potential of the optimized niosomes. 68.03% of the medication was released after 48 hours. Conclusion: To address the issues with traditional oral ceritinib distribution, ceritinib-loaded niosomes were created in this study as a potential substitute.

Keywords: Ceritinib, Lung cancer, Niosomes, Central composite design.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.45

How to cite this article: Palva RS, Yadav VK, Suthar RM, Shete R. Design, Development and Characterization of a Niosomal Anticancer Drug Delivery System Formulation. International Journal of Drug Delivery Technology. 2024;14(3):1572-1577.

REFERENCES

  1. Bray , Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A.,Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimatesof Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/ caac.21492.
  2. Zappa C., Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016;5:288–300. doi: 10.21037/tlcr.2016.06.07.
  3. Planchard , Besse B. Lung cancer in never-smokers. Eur.Respir. J. 2015;47:1214–1217. doi: 10.1183/09031936.00046915.
  4. Ahmad , Akhter S., Rizwanullah M., Amin S., Rahman M., Ahmad M.Z., Rizvi M.A., Kamal M.A., Ahmad F.J. Nanotechnology-based inhalation treatments for lung cancer: State of the art. Nanotechnol. Sci. Appl. 2015;8:55–66. doi: 10.2147/NSA.S49052.
  5. An , Shi C.X., Guo H., Xie S.M., Yang Y.Y., Liu Y.N., LiuZ.H., Zhou C.Z., Niu F.J. Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small cell lung cancer. Pharm. Dev. Technol. 2019;24:1164–1174. doi: 10.1080/10837450.2019.1647236.
  6. Yadav sunil kumar and Mishra manoj kumar. “Niosome: An approach towards targeted drug delivery system” Pharmaceutical Science, 2016.
  7. Sanklecha M, and Pande V.V. “Review on niosomes.” Austin pharmacology & pharmaceutics, 2018, 3(2), 1016.
  8. Din, F.U.; Aman, W.; Ullah, I.; Qureshi, S.O.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. J. Nanomed. 2017, 12, 7291–7309. doi: 10.2147/IJN.S146315.
  9. Ge, X.; Wei, M.; He, S.; Yuan, W. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics 2019, 11, 55. doi: 10.3390/
  10. Shirsand, S. B., and Ganesh G. Keshavshetti. “Recent advances in niosomal drug delivery A ” Res. J. Life Sci. Bioinform. Pharm. Chem. Sci 3. 2019, 514-531. doi: 10.26479/2019.0503.43.
  11. Iman Akbarzadeh and Mohammad Tavakkoli Yaraki. “Preparation, physicochemical properties, in-vitro evaluation and release behavior of cephalexin- loaded niosomes.” International Journal of Pharmaceutics. 2019. doi:10.1016/j. 2019.118580.
  12. Asgar Ali and Mohd Qumbar. “Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity.” Biomedicine & Pharmacotherapy 93, 2017, 255–266.
  13. Zerrin Sezgin-Bayindir and Mustafa Naim Antep. “Development and Characterization of Mixed Niosomes for Oral Delivery Using Candesartan Cilexetil as a Model Poorly Water-Soluble ” American Association of Pharmaceutical Scientists. 2014. doi: 10.1208/s12249-014-0213-9.
  14. Veldurthi Ravalika and Abbaraju Krishna “Formulation and Evaluation of Etoricoxib Niosomes by Thin Film Hydration Technique and Ether Injection Method.” Nano Biomed. Eng., 2017, 9(3): 242-248. doi:10.5101/nbe.v9i3.p242-248.
  15. Moazeni, Esmaeil, et al. “Formulation and in-vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery.” Journal of microencapsulation 7, 2010, 618-627. doi: 10.3109/02652048.2010.506579.
  16. Mohd Mujeeb and Md. Shamsir Alam. “Embelin-loaded oral niosomes ameliorate streptozotocin-induced diabetes in Wistar ” Biomedicine & Pharmacotherapy 97, 2018, 1514–1520. doi. org/10.1016/j.biopha.2017.11.073